First-Line Avelumab/Axitinib Shows Early Antitumor Activity in mRCC

Despite high rates of toxicity, a first-line tyrosine kinase inhibitor/immunotherapy combination exhibits promising antitumor activity in metastatic renal cell carcinoma.

Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Conferences/ASCO Renal Cell Carcinoma Genitourinary Cancers News Source Type: news